[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100618800":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":26,"locations":32,"responsibleParty":46,"collaborators":25,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":52,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":25,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":70,"overallStatus":34,"whyStopped":25,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":82},{"fullName":5,"class":6},"Kangbuk Samsung Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Periodic CGM Use","EXPERIMENTAL","All participants first wear FreeStyle Libre 2 CGM continuously for 12 weeks to establish baseline glucose patterns. Only those with at least 50% sensor active time proceed to randomization. After randomization, participants in this arm wear CGM intermittently for 2 weeks at weeks 2, 6, and 10 (±3 days each). Each sensor is worn for 14 days then removed. During non-wearing periods, no CGM is used. Participants receive education on diet adjustment based on postprandial glucose from CGM. Existing diabetes medications are maintained without changes throughout the study.",[13],"Device: FreeStyle Libre 2 Continuous Glucose Monitoring",{"label":15,"type":16,"description":17,"interventionNames":18},"Continuous CGM Use","ACTIVE_COMPARATOR","All participants first wear FreeStyle Libre 2 CGM continuously for 12 weeks to establish baseline glucose patterns. Only those with at least 50% sensor active time proceed to randomization. After randomization, participants in this arm continue to wear CGM continuously for 12 weeks with sensor replacement every 14 days (total 6 replacements). Participants receive education on diet adjustment based on postprandial glucose from CGM. Existing diabetes medications are maintained without changes throughout the study.",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DEVICE","FreeStyle Libre 2 Continuous Glucose Monitoring","FreeStyle Libre 2 continuous glucose monitoring system consisting of a sensor worn on the upper arm that measures interstitial glucose levels continuously for up to 14 days. Data is transmitted to a smartphone app (FreeStyle LibreLink). The sensor is a Class 3 medical device approved by MFDS (Korea). Participants receive education on adjusting diet based on postprandial glucose patterns observed through CGM. Existing diabetes medications (oral agents and\u002For GLP-1 agonists) are maintained without changes throughout the intervention period.",[15,9],null,[27],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},"Sun-Joon Moon, MD, PhD","CONTACT","+82-2-2001-1550","ipleat.m@gmail.com",[33],{"facility":5,"status":34,"city":35,"state":36,"zip":37,"country":36,"countryCode":25,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Seoul","South Korea","03181",{"type":39,"coordinates":40},"Point",[41,42],126.9784,37.566,{"lat":42,"lon":41},[45],{"name":28,"role":29,"phone":30,"phoneExt":25,"email":31},{"type":47,"investigatorFullName":48,"investigatorTitle":49,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Sun Joon, Moon","Professor","100618800","continuous-glucose-monitoring-in-non-insulin-treated-type-2-diabetes-continuous-vs-periodic-use-100618800",false,"NCT07336329","Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use","Effectiveness of Periodic Use of Continuous Glucose Monitoring After Three Months of Continuous Use in Patients With Non-Insulin-Treated Type 2 Diabetes Patients: A Multicenter, Randomized, Parallel-Group, Open-Label, Non-Inferiority, Investigator-Initiated Trial","PERIODIC-CGM","Inclusion Criteria:\n\n* Adults aged 19 to 80 years at the time of informed consent\n* Adults with type 2 diabetes not using insulin\n* Patients treated with GLP-1 agonist, oral hypoglycemic agents, and\u002For lifestyle modifications\n* Patients who have maintained stable diabetes treatment for at least 3 months without changes\n* HbA1c between 7.5% and 10.0%\n* Willing to wear personal continuous glucose monitoring device (CGM)\n* Willing to install and use CGM-linked app on personal smartphone with continuous access to WIFI or cellular data\n* Able to read and write Korean as judged by investigator\n* Willing to use medically acceptable contraception until end of study (sterile status, intrauterine device, or concurrent use of male\u002Ffemale barrier method with spermicide)\n* Fully informed about the clinical trial and voluntarily consenting to participate\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus\n* Gestational diabetes mellitus\n* History of pancreatectomy\n* Continuous or intermittent insulin therapy for 7 days or more within 3 months\n* Oral or IV steroid treatment within 1 month prior to informed consent\n* Serious infection, surgery (scheduled or history), or severe trauma within 3 months prior to informed consent\n* History of malignancy within 1 year prior to informed consent (except thyroid cancer)\n* On hemodialysis or peritoneal dialysis or eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m2\n* Unable to avoid the following concomitant medications, devices, or treatments during the study: CGM other than study device, X-ray\u002FMRI\u002FCT scans, radiofrequency thermal therapy, implantable devices such as pacemakers, immunosuppressants, steroids, IV vitamin preparations, cancer treatment, hemodialysis\u002Fperitoneal dialysis, insulin therapy\n* Uncontrolled thyroid disease or clinically significant severe endocrine disorders (Cushing's syndrome, pheochromocytoma, etc.)\n* Severe allergic reaction to skin adhesives (e.g., dyspnea, severe rash, edema)\n* Whole blood donation within 60 days, apheresis within 30 days, or blood transfusion within 90 days prior to device application\n* Judged by investigator as unable to handle continuous glucose monitoring device\n* Pregnant or lactating women\n* Planning pregnancy within 1 year\n* Otherwise judged by investigator as inappropriate for participation in this clinical trial","ALL","19 Years","80 Years",{"count":62,"type":63},150,"ESTIMATED","INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to test whether wearing a continuous glucose monitor (CGM) part-time works as well as wearing it full-time in adults with type 2 diabetes who do not use insulin. The main questions it aims to answer are:\n\n* Does wearing CGM part-time (2 weeks per month) control blood sugar as well as wearing it continuously?\n* How do the two wearing patterns compare for blood sugar levels throughout the day, weight, blood pressure, and patient satisfaction?\n\nResearchers will compare part-time CGM use to continuous CGM use to see if part-time use is just as effective for blood sugar control.\n\nAll participants will:\n\n* Wear a CGM device continuously for 3 months to learn how their blood sugar responds to different foods and activities\n* Then be randomly assigned to wear CGM either part-time (2 weeks each month) or continuously for another 3 months\n* Replace the CGM sensor on their arm every 2 weeks\n* Use a smartphone app to track their blood sugar readings\n* Visit the clinic 3 times for blood tests and check-ups\n* Receive education on adjusting diet based on their CGM readings\n* Keep their current diabetes medications unchanged during the study\n\nThe study will last about 6 months total. Participants will use the FreeStyle Libre 2 CGM device, which is already approved for use in people with diabetes.",[69],"Diabetes Mellitus, Type 2",[71,72],"type 2 diabetes","continuous glucose monitoring","2026-01-10",{"date":75,"type":76},"2026-01-13","ACTUAL",{"date":78,"type":76},"2026-01-02",{"date":80,"type":63},"2027-06-30",{"name":5,"class":6},1]